Neoplasms

All Conditions

Rare Diseases

Chordoma

Neoplasms, Germ Cell and Embryonal

Neoplasms by Histologic Type

Antineoplastic Agents

All Drugs and Chemicals

Amino Acids

Afatinib

Tyrosine Kinase Inhibitors

Protein Kinase Inhibitors

Enzyme Inhibitors

Tyrosine

Subject meeting the inclusion criteria will take afatinib (40 mg daily) orally, 4 weeks for a cycle.

Subjects will receive evaluations at the beginning of treatment, after every three cycles and at the end of the whole study.

Qilin Zhang, MD

This is a single arm, open label, single center, and prospective, interventional study to explore clinical efficacy of afatinib in patients with chordoma of skull base. Subject meeting the inclusion criteria will take afatinib (40 mg daily) orally, 4 weeks for a cycle. The primary objective is to assess the efficacy of afatinib in chordoma of skull base by objective response rate (ORR). The Secondary objectives is to assess progression free survival (PFS), overall survival (OS), tumor response duration and tumor shrinkage degree in patients with chordoma of skull base after using afatinib; to evaluate the safety and tolerability of afatinib in patients with chordoma of skull base.

Study to Evaluate the Efficacy of Afatinib in Skull Base Chordoma

An Open-label, Single-arm, Interventional Clinical Study to Evaluate the Efficacy of Afatinib in Skull Base Chordoma

Proportion of patients with reduction in tumor volume to a predefined value for a minimum period. Generally, ORR is defined as the sum of complete response and partial response. The best response, that is, the best response throughout the study, will be evaluated.

duration from the date of inclusion until the date of objective tumor progression or death.

duration from the date of inclusion until the date of death.

duration of partial response and complete response, that is, duration from effective date to the date of proved tumor progression.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Study to Evaluate the Efficacy of Afatinib in Skull Base Chordoma	NCT05519917	Chordoma of Cli...	Afatinib	18 Years -	Huashan Hospital
Study to Evaluate the Efficacy of Afatinib in Skull Base Chordoma	NCT05519917	Chordoma of Cli...	Afatinib	18 Years -	Huashan Hospital

Spots Global Cancer Trial Database for chordoma of clivus